Assessment of Food Supplement Consumption in Polish Population of Adults.

In recent years, there has been a great interest in food supplements. However the use of food supplements can be associated with the risk of excessive intake of vitamins or minerals which may have adverse health effects. Assessment of food supplement consumption in the adult population in Poland.

Polymorphisms and haplotypes of the NBS1 gene in childhood acute leukaemia.

DNA repair gene polymorphisms and mutations may influence cancer risk. The product of the NBS1 gene, nibrin, is functionally involved in the double-strand DNA break repair system. Heterozygous, germline mutations of the NBS1 gene are associated with an increased risk of tumours.

Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours.

Homozygous mutation 657del5 within the NBS1 gene is responsible for the majority of Nijmegen breakage syndrome (NBS) cases. NBS patients are characterised by increased susceptibility to malignancies mainly of lymphoid origin. Recently it has been postulated that heterozygous carriers of 657del5 NBS1 mutation are at higher risk of cancer development.

Increased risk of larynx cancer in heterozygous carriers of the I171V mutation of the NBS1 gene.

The high incidence of multiple primary tumors (MPT) is a significant problem in head and neck tumor treatment. Recent studies suggest that carriers of heterozygous mutations in the NBS1 gene have an increased risk of malignant tumor development. The aim of our research was to assess the frequency of NBS1 mutations in patients with larynx cancer only (LC) and with MPT.

Regional distribution of heterozygous 657del5 mutation carriers of the NBS1 gene in Wielkopolska province (Poland).

The homozygous 657del5 mutation, called Slavic mutation, of the NBS1 gene, causes the Nijmegen Breakage Syndrome (NBS). This syndrome is connected with a high incidence of malignancies in early childhood. A high frequency of NBS heterozygotes was found among patients with melanoma, breast, ovary and prostate cancer.